- Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs (reuters.com)More drugmakers hike U.S. prices as new year begins (reuters.com)
Drugmakers including Pfizer Inc, GlaxoSmithKline PLC and Sanofi SA are planning to hike U.S. list prices on more than 200 drugs in the United States...according to drugmakers...Nearly all of the price increases will be below 10%, and around half of them are in the range of 4 to 6%...The median price increase is around 5%...READ MORE
- Chinese court sentences ‘gene-editing’ scientist to three years in prison (reuters.com)
A Chinese court sentenced the scientist who created the world’s first “gene-edited” babies to three years in prison...for illegally practising medicine and violating research regulations...He Jiankui...said he had used gene-editing technology known as CRISPR-Cas9 to change the genes of twin girls to protect them from getting infected with the AIDS virus in the future...The backlash in China and globally about the ethics of his research and work was fast and widespread...“They have crossed the bottom line of ethics in scientific research and medical ethics.”...READ MORE
- 2019 Year in Review (pharmacytimes.com)
Nicole Grassano, PTNN, Year in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- This Week in Managed Care: December 20, 2019 (ajmc.com)
Christina Mattina, welcome to This Week in Managed Care from the Managed Markets News Network
- NCPA stands with NY patients, pharmacists after Cuomo veto (chaindrugreview.com)AARP praises Governor Cuomo’s plan to tackle high Rx drug costs (chaindrugreview.com)
Despite aggressive advocacy efforts by state-based pharmacy organizations and individual New York pharmacists, Gov. Andrew Cuomo this week vetoed legislation to help to rein in costly pharmacy benefit manager practices by giving the superintendent of insurance licensing and regulatory authority over PBMs. This regulatory authority would put an end to the lack of transparency, oversight, and accountability that has allowed PBMs to engage in anticompetitive practices to the harm of the state’s patients and small-business community pharmacies...READ MORE
- Nevada’s 2019 Hospital Safety Rankings Are Out
Leapfrog’s highest “A” rated hospitals for 2019 has remained unchanged from last year. These are Henderson Hospital, Mountainview Hospital, Northern Nevada Medical Center, Renown South Meadows Medical Center, and St. Mary's Regional Medical Center of Reno.
The Leapfrog Group hospital grading system is based on Centers for Medicare & Medicaid Services data collection and represents a single metric that evaluates a hospital’s overall safety performance. The nonprofit is dedicated to transparency and has created the Leapfrog Hospital Safety Grade as a quality standard for comparing health care institutions.
The “B” team consists of North Vista Hospital, Valley Hospital Medical Center, St. Rose Dominican Hospitals - Siena Campus, St. Rose Dominican Hospitals - San Martin Campus, and Renown Regional Medical Center.
The good news is two of these hospitals have shown a marked safety improvement by moving up from a “C” rating to a “B” rating; these are: Valley Hospital Medical Center, and Renown Regional Medical Center.
These hospitals are to be applauded for consistently maintaining high standards and striving to improve patient care.
The bad news is the University Medical Center of Southern Nevada continues to struggle with its’ “D” rating.
By Chase
12.30.2019
- Drug Shortages, Product Standardization Plague IV Drug Delivery (drugtopics.com)
Ongoing threats to the safety of intravenous (IV) drug delivery include drug shortages and lack of IV product standardization, according to an expert panel...The panel of health care providers developed recommendations...The findings...were published in the American Journal of Health-System Pharmacy.
The panel’s findings include:
- The panel believes in the overall superiority of manufacturer ready-to-use products, and says they are the safest IV drug delivery systems, followed by outsourced, ready-to-use, pharmacy compounded, point-of-care activated, and nonpharmacy compounded at point of care.
- Drug shortages and lack of standardization are the 2 most significant threats to IV drug safety.
- Variations in IV medication concentrations during transitions of care within the same institution or between different facilities can increase the likelihood of a medication error, leading the panel to identify lack of standardization as a major threat to safety.
- Manufacturer-prepared products are the safest IV drug delivery system, and manufacturer-prepared, ready-to-administer products are preferred for patient use whenever possible...
- Specialized education, training, certification, and competency with regard to compounding of sterile preparations should be required for pharmacists, pharmacy technicians, and other involved health care providers...
- A legislative and regulatory framework that supports and encourages IV medication safety in all settings (such as physician offices) should be developed…READ MORE
- California pharmacies rarely take back unused opioids (reuters.com)Unwanted Medication Disposal: Audit of California Pharmacy Advice (annals.org)
Only 1 in 10 California pharmacies have programs to take back unused prescription opioids and just one in five give consumers accurate disposal information, according to a study that suggests drugstores could do more to help combat substance abuse...The study results suggest that many pharmacies may be falling short as educators and as places for safe disposal...READ MORE
- This Week in Managed Care: The Top Stories of 2019 (ajmc.com)
Christina Mattina, welcome to This Week in Managed Care from the Managed Markets News NetworkHere are the results of our online poll of the top healthcare stories for 2019.
5. A judge strikes down Medicaid work rules in Kentucky and Arkansas.
4. The uninsured rate hits a 4-year high.
3. Doctors link a mysterious lung illness to vaping.
2. An appeals court brings uncertainty to the future of the ACA.
1. Dr Scott Gottlieb steps down as FDA commissioner.
- Medical breakthroughs, looser FDA made biotech stocks one of the decade’s best investments (cnbc.com)
Biotechnology was one of the decade’s best investments as a dizzying pace of clinical innovation fueled the discovery of treatments once thought beyond the reach of modern medicine. A more aggressive FDA also aided the trend...An investor who purchased shares of the iShares Nasdaq Biotechnology ETF in December 2009 is now up more than 350% in returns. In other words, a $1,000 stake in biotech in 2009 would now be worth over $4,500...Industry experts point to breakthroughs in the treatment of diseases like hepatitis C, multiple sclerosis and a variety of malignancies for biotech’s big decade and the eye-popping profits the industry’s therapies promise...READ MORE










